No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MNPR Monopar Therapeutics
- 0.6570
- +0.0070+1.08%
Close Apr 24 16:00 ET
- 0.6303
- -0.0267-4.06%
Post 17:38 ET
11.47MMarket Cap-1077P/E (TTM)
0.6800High0.6300Low39.45KVolume0.6800Open0.6500Pre Close25.75KTurnover0.47%Turnover RatioLossP/E (Static)17.45MShares1.750052wk High2.05P/B5.46MFloat Cap0.273952wk Low--Dividend TTM8.31MShs Float48.0000Historical High--Div YieldTTM7.69%Amplitude0.2739Historical Low0.6520Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
WILMETTE, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patient
Monopar Therapeutics Files Provisional Patent for New MNPR-101 Construct
Monopar Therapeutics (MNPR) said Tuesday it has filed a provisional patent application with the US Patent and Trademark Office for certain advancements in its MNPR-101 radiopharmaceutical program. The
Express News | Monopar Announces Filing of Patent Protecting Mnpr-101 Radiopharma Optimization Findings
Express News | Monopar Therapeutics Shares Are Trading Higher After JonesTrading Upgraded the Stock From Hold to Buy
Express News | JonesTrading Upgrades Monopar Therapeutics to Buy, Announces $2 Price Target
Express News | Monopar Therapeutics Inc : Jonestrading Raises to Buy
Comments
Update
$Monopar Therapeutics(MNPR.US$ Monopar Announces Filing of Patent Protecting Mnpr-101 Radiopharma Optimization Findings
1
3
$Monopar Therapeutics(MNPR.US$ Monopar Therapeutics Inc (MNPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from JonesTrading upgraded the rating on the stock to a Buy and gave it a $2.00 price target.
Update
$Monopar Therapeutics(MNPR.US$ Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
2 MINUTES AGO, 8:00 AM EDT
VIA GLOBENEWSWIRE
2
$Monopar Therapeutics(MNPR.US$ Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg